Chinese biophysicist Rao Zhihe has taken the helm as the first strategic scientist at a new innovation hub designed to deepen collaboration between China and Thailand in health and life sciences. The appointment signals Beijing's strategic interest in positioning itself as a regional research leader while expanding institutional partnerships across Southeast Asia.
Rao, a professor at both Tsinghua and ShanghaiTech universities, has spent years working on natural anti-Covid products alongside researchers at Mahidol University. Early in the coronavirus pandemic, his team identified two parts of the virus that could be targeted by drugs—and he made the decision to share that information with the global scientific community rather than restrict it to Chinese institutions.
"We shared them with more than 300 universities, research institutes and companies that approached our team before the findings were published," Rao said during an interview in Bangkok last month on his first trip abroad in three years. That openness in sharing early pandemic research stands in contrast to broader geopolitical tensions over scientific collaboration and intellectual property.
The Research Imperative
Rao's rationale for the broad distribution was straightforward: speeding up the development of effective drugs required international effort, not competition. Speaking at a forum organized by the Association of Pacific Rim Universities, he emphasized that the world "desperately" needed a broad-spectrum and effective antiviral drug—something his team continues working toward. He framed the challenge as requiring "joint efforts from international scientists," a recognition that even state-backed research programs operate within limits.
The forum itself brought together industry and university leaders to discuss cross-border biomedical research partnerships in the Asia-Pacific region, with a focus on pandemic prevention. That convening of private and academic sectors reflects a model where government-backed research institutions collaborate with market-driven enterprises rather than attempting to monopolize scientific advancement.
Strategic Positioning
Rao was direct about China's regional ambitions. "I believe China and Thailand have good room for cooperation," he told forum attendees. The appointment of a strategic scientist to lead the innovation hub underscores how Beijing is using institutional frameworks to build research relationships across the region. Thailand's participation suggests receptiveness to these partnerships, though the dynamics of such collaborations—particularly around intellectual property and research autonomy—warrant scrutiny.
The hub's focus on health and life sciences taps into genuine regional vulnerabilities. The pandemic exposed gaps in Asia-Pacific disease surveillance and drug development capacity. By positioning itself as a collaborative partner rather than a competitor, China is advancing both scientific and diplomatic objectives simultaneously.
Rao's own trajectory—from identifying viral targets early in the pandemic to now leading a regional innovation initiative—illustrates how individual researchers and their institutions can become instruments of state strategy. His willingness to share findings broadly suggests genuine scientific commitment, yet his prominent role in this hub also reflects Beijing's confidence in using research partnerships as a vehicle for influence.
Why This Matters:
This development carries implications for how biomedical research and pandemic preparedness unfold across Asia. Private companies and universities in the region will increasingly interact with Chinese-led research initiatives, raising questions about data flows, intellectual property ownership, and research independence. The hub model—combining government backing with academic and industry participation—represents a form of state-directed collaboration that differs markedly from purely market-driven research partnerships. For policymakers concerned with maintaining research autonomy and protecting proprietary discoveries, understanding the governance structures and incentive mechanisms within such hubs is critical. The success or failure of China-Thailand collaboration on antiviral drugs will also signal whether cross-border research partnerships can function effectively amid broader geopolitical competition, or whether scientific collaboration increasingly becomes another arena of strategic rivalry.